More than 700 follow-on biologic therapies are currently in development, and they are expected to account for around a quarter of the $100 billion-worth of sales stemming from off-patent biologic drugs by the end of this decade, according to new research.
read at
Filed under: ANTIBODIES, Biosimilar drugs, Monoclonal antibody Tagged: antibodies, biosimilars, Monoclonal Antibodies
